BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/23/2021 6:10:00 AM | Browse: 233 | Download: 274
 |
Received |
|
2021-04-19 04:42 |
|
Peer-Review Started |
|
2021-04-19 04:45 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-08 07:13 |
|
Revised |
|
2021-08-02 20:08 |
|
Second Decision |
|
2021-11-30 03:43 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-11-30 19:12 |
|
Articles in Press |
|
2021-11-30 19:12 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-12-21 07:11 |
|
Publish the Manuscript Online |
|
2021-12-23 06:10 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Review |
| Article Title |
Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mouhamed Nashawi, Mahmoud S Ahmed, Toka Amin, Mujahed Abualfoul and Robert Chilton |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mouhamed Nashawi, MD, Academic Research, Staff Physician, Department of Internal Medicine, Baylor Scott and White All Saints Medical Center, 1400 8th Ave, Fort Worth, TX 76132, United States. nashawi@livemail.uthscsa.edu |
| Key Words |
Sodium-glucose cotransporter 2; Phosphate; Hyperphosphatemia; Cardiovascular; Canagliflozin; Dapagliflozin; Empagliflozin; Endothelial |
| Core Tip |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have received increased attention regarding their pleiotropic effects given their markedly impressive performance in cardiovascular outcome trials (CVOT). Preliminary evidence shows that their role as antidiabetic agents is not their sole mechanism in achieving these cardiorenal protective properties. Therefore, investigation in the auxiliary properties that they hold concomitant with glucose control, vindicated by not only CVOTs, but meta-analyses, retrospective studies, and case reports has led to increased interest in delineating their global pharmacodynamic effects across the spectrum of gene expression and molecular modulation to end-organ translational biology. Such a full profile of their effects is not yet understood given the refractory period between clinical evidence supporting their utilization and a proclivity for their implementation in practical clinical environments. In this review, we answer inquiries regarding how via a multifarious avenues, SGLT2 inhibitors, while carrying a negative effect of induced phosphatemia (which is deleterious to the heart), compensate for this phenomenon, retaining their propensity for net cardiac benefit upon pharmacotherapeutic administration under appropriate clinical circumstances. |
| Publish Date |
2021-12-23 06:10 |
| Citation |
Nashawi M, Ahmed MS, Amin T, Abualfoul M, Chilton R. Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy. World J Cardiol 2021; 13(12): 676-694 |
| URL |
https://www.wjgnet.com/1949-8462/full/v13/i12/676.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v13.i12.676 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
